top of page
The Professional Network for Healthcare Experts
FDA grants accelerated approval to Etcamah combination for ESR1-mutated advanced breast cancer
The FDA has granted accelerated approval to Etcamah in combination with a CDK4/6 inhibitor for adults with ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
nuaxia
Sep 82 min read
EU approves Etcamah and advances Enhertu combination for biomarker-defined breast cancers
The two regulatory decisions could expand first-line treatment options for patients with ESR1-mutant ER-positive disease and HER2-positive metastatic breast cancer, although Enhertu still requires European Commission approval.
nuaxia
Jul 312 min read
bottom of page